Tempus AI TEM is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital pathology, ...

Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies. The company grew its ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best digital health stocks to buy now. Wall Street sentiment toward Tempus AI strengthened on November 5, 2025, following the company's Q3 results, with ...

The smart money has taken a liking to Tempus AI (TEM). Though the mid-cap is choppy, the growth profile and recent margin gains are hard to ignore as applied AI looks to pick up more traction. Tempus ...

In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...

Prior to the start of this week, Tempus AI (NASDAQ: TEM) stock had locked in a 161% gain since the start of the year -- an impressive performance for the healthcare company that's pioneering ...

On Thursday, Tempus AI, Inc. (NASDAQ:TEM) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. The update ...

Tempus AI is a Buy for long-term growth, driven by its shift to a data/AI platform and accelerating genomics volume fueling high-margin revenue. Strategic deals (AstraZeneca/Pathos) and the Paige ...

AI-powered data company Tempus AI announced it will acquire Paige, an AI-enabled diagnostic platform for oncologists and pathologists, for $81.25 million. Tempus said the acquisition will help the ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial-intelligence-powered programs for spotting the signs of cancer. The deal totals $81.25 million, ...

There’s always something new at SL Green’s 11 Madison Ave. Last week’s splash was Eleven Madison Park chef Daniel Humm’s announcement that the three-Michelin-star restaurant will drop its vegan-only ...

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, ...